ARA-290
ARA-290 (also called Cibinetide) is an 11-amino-acid peptide derived from erythropoietin's helix B region — engineered to carry EPO's anti-inflammatory and neuroprotective effects without stimulating red blood cell production. People run it primarily for neuropathic pain, where roughly two-thirds of community reports describe benefit; the clinician-tier guidance points to 2 mg subcutaneous weekly as the reference dose, though community reports don't yet document consistent dosing patterns. There's no FDA-approved indication, so all human use is off-label or through compounding, and individual response across captured reports varies considerably.
Research Evidence
Evidence shape
ARA-290's clinical evidence base is empty: zero registered human trials exist, and the only mapped research sits entirely in preclinical and mechanistic work. That leaves animal-model findings as the whole foundation — which establishes biological plausibility but provides no efficacy or safety signal in humans. The absence of any sponsored or independent trial program is itself a data point; anyone looking for human evidence will not find it.
Anecdotal efficacy
Side effects
Clinical research side effects
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How ARA-290 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
- Timing
- unspecified
- Cycle
- unspecified
2 completed trials identified; trial dosing not reliably extracted from registry data.
- Frequency
- weekly
- Timing
- unspecified
- Route
- subQ
- Cycle
- unspecified
Clinician protocols dose 2 mg weekly subQ (2 sources).
No structured protocol details captured for this tier yet.
Community reports mention use for neuropathic pain relief (54.5% positive in 11 reports) and tissue repair/neuroprotection (100% positive in 3 reports). No specific dose information was consistently reported.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Peptide feedback
0 forum repliesLive community discussion for ARA-290, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.